Pharmaceutical Preparations · DE · CIK 1783183
Develops and commercializes novel GI disease treatments, notably vonoprazan for acid reduction and H. pylori
Comparable business profile · signals at a glance
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2025 | Breedlove Robert CharlesPrincipal Accounting Officer | Sell | 524 | $13.51 | $7K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.